


Product Name : Abemaciclib
Cat. No. : PC-20589
CAS No. : 1231929-97-7
Molecular Formula : C₂₇H₃₂F₂N₈
Molecular Weight : 506.61
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



CAS: 1231929-97-7

Biological Activity

Abemaciclib (LY2835219) is a potent, selective and competitive ATP CDK4/6 inhibitor with K_i values of 0.6 and 2.4 nM for CDK4/cyclin D1 and CDK6/cyclin D1, respectively.

Abemaciclib (LY2835219) inhibits CDK4/cyclin D1 and CDK6/cyclin D1 with IC₅₀ of 2 and 10 nM, respectively, with high selectivity against CDK1/cyclin B1, CDK2/cyclin E, and CDK7/Mat1/cyclin H.

Abemaciclib (LY2835219) is a potent inhibitor of Rb phosphorylation (IC₅₀=120 nM) in colo-205 cells, induces a complete cell cycle arrest and suppresses expression of several Rb-E2F-regulated proteins.

Abemaciclib (LY2835219) inhibits tumor growth in human tumor xenografts representing different histologies in tumor-bearing mice.

Abemaciclib (LY2835219) in combination with gemcitabine enhanced in vivo antitumor activity without a G1 cell cycle arrest in calu-6 xenografts.

References

Tate SC, et al. Clin Cancer Res. 2014 Jul 15;20(14):3763-74.

Gelbert LM, et al. Invest New Drugs. 2014 Oct;32(5):825-37.

Yadav V, et al. Mol Cancer Ther. 2014 Oct;13(10):2253-63.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com